Motor Function clinical trials

Explore recruiting motor function clinical trials.

Recruiting motor function studies right now

Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Motor Function trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

EVALUATION OF THE EFFICACY AND SAFETY OF METFORMIN IN THE MYOTONIC DYSTROPHY TYPE I (STEINERT’S DISEASE). PHASE III PROSPECTIVE, MULTICENTRE, RANDOMISED, DOUBLE-BLIND CONTROLLED STUDY.

France

Therapeutic confirmatory (Phase III) EU CTIS Study details

Prospective pilot study of L-dopa treatment in patients with a neurodevelopmental disorder linked to a pathogenic variant of the CTNNB1 gene

France

Therapeutic exploratory (Phase II) EU CTIS Study details

An Open-Label Extension of Study HGT-MLD-070 Evaluating Long Term Safety and Efficacy of Intrathecal Administration of HGT-1110 in Patients with Metachromatic Leukodystrophy

Czechia, Denmark, Germany, France, Italy

Phase I and Phase II (Integrated)- Other EU CTIS Study details

A Phase IIb, Monocentric, Non-Profit, Open-label Trial for the Intrathecal Administration of AAV9/AP4M1 for Hereditary Spastic Paraplegia Type 50 (SPG50)

Italy

Therapeutic exploratory (Phase II) EU CTIS Study details

A Randomized, Double-Blind, Placebo-Controlled, Study to Evaluate the Efficacy and Safety of Taldefgrobep Alfa in Ambulatory and Non-Ambulatory Participants with Spinal Muscular Atrophy with Open-Label Extension (RESILIENT)

Italy, Poland, Spain, Germany, Belgium, Czechia +1 more

Therapeutic confirmatory (Phase III) EU CTIS Study details

Darbepoetin for Ischemic Neonatal Stroke to Augment Regeneration

Netherlands

Therapeutic exploratory (Phase II) EU CTIS Study details

Motor Function trials by city

Motor Function in Toronto Motor Function in Vancouver Motor Function in Montreal Motor Function in Calgary Motor Function in Edmonton Motor Function in Ottawa Motor Function in Winnipeg Motor Function in Quebec City Motor Function in Hamilton Motor Function in Kitchener Motor Function in London Motor Function in Halifax Motor Function in New York Motor Function in Los Angeles Motor Function in Chicago Motor Function in Houston

Other conditions

Obesity Type 2 diabetes Type 1 diabetes Prediabetes Weight loss Metabolic syndrome High cholesterol High triglycerides High blood pressure PCOS Hypothyroidism Thyroid disease Gout Fatty liver disease (NAFLD/NASH) Heart failure Coronary artery disease Atrial fibrillation Stroke Stroke recovery Peripheral artery disease Pulmonary hypertension Deep vein thrombosis Chronic kidney disease Diabetic kidney disease